School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, South Korea.
PLoS One. 2019 Feb 28;14(2):e0212905. doi: 10.1371/journal.pone.0212905. eCollection 2019.
Therapeutic ineffectiveness involves drug-related therapeutic failure, inefficacy or resistance and has not been sufficiently studied. Objective of our study was to evaluate reporting trends in therapeutic ineffectiveness by year and describe factors affecting therapeutic ineffectiveness using the Korea Adverse Event Reporting System. Proportion of therapeutic ineffectiveness reports was based on total submitted reports between 2000 and 2016. Utilizing 2016 alone, we compared the characteristics of therapeutic ineffectiveness with age group and gender matching by random extraction. We conducted a logistic regression analysis to estimate reporting odds ratios (ROR) and its 95% confidence intervals (CI) for reports by type of reporters, e.g., doctors, pharmacists, or consumers. We presented most frequent reports by the anatomical main groups and therapeutic subgroups according to the Anatomical Therapeutic Chemical (ATC) classification system. For the 17-years, the proportion of therapeutic ineffectiveness adverse drug reactions reporting ranged from 0.0% to 3.7% between 2000 and 2016. Of 228,939 reports, 2,797 (1.2%) were submitted in 2016. Consumers accounted for 6.92% of reports and doctors accounted for 45.49%, in which, consumers were more likely to report therapeutic ineffectiveness than doctors (adjusted ROR 3.98; 95% CI, 2.92 to 5.41). According to the ATC classification system, "nervous system" was the most frequently reported anatomical group (18.7%) and "parathyroid hormones and analogues" was reported most frequently in the pharmacological subgroup (23.7%). Teriparatide, a drug used to treat osteoporosis, had the most reports (11.0%). Therapeutic ineffectiveness reports may be used as a scientific tool for the reevaluation of respective drugs in order to confirm of its therapeutic effects.
治疗无效性涉及与药物相关的治疗失败、无效或耐药性,且尚未得到充分研究。我们的研究目的是评估通过年份评估治疗无效性报告的趋势,并使用韩国不良事件报告系统描述影响治疗无效性的因素。治疗无效性报告的比例基于 2000 年至 2016 年期间提交的总报告。仅利用 2016 年的数据,我们通过随机抽取,比较了治疗无效性与年龄组和性别匹配的特征。我们进行了逻辑回归分析,以估计报告者类型(例如医生、药剂师或消费者)的报告的报告比值比(ROR)及其 95%置信区间(CI)。我们根据解剖治疗化学(ATC)分类系统,按照解剖主要群组和治疗亚组展示了最常见的报告。在 17 年间,2000 年至 2016 年期间,治疗无效性不良反应报告的比例在 0.0%至 3.7%之间。在 228939 份报告中,2016 年提交了 2797 份(1.2%)。消费者占报告的 6.92%,医生占 45.49%,其中消费者比医生更有可能报告治疗无效性(调整后的 ROR 3.98;95%CI,2.92 至 5.41)。根据 ATC 分类系统,“神经系统”是最常报告的解剖组(18.7%),而“甲状旁腺激素及其类似物”在药理学亚组中报告最多(23.7%)。特立帕肽是一种用于治疗骨质疏松症的药物,报告最多(11.0%)。治疗无效性报告可用作重新评估相应药物的科学工具,以确认其治疗效果。